Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women - Concepedia

Concepedia

Publication | Open Access

Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women

DOI Full Paper Access

111

Citations

33

References

2013

Year

Jessica A. Kahn, Jiahong Xu, Bill G. Kapogiannis, Bret J. Rudy, René Gonin, Nancy Liu, Craig M. Wilson, Carol Worrell, Kathleen Squires

Clinical Infectious Diseases

Abstract

In a sample of HIV-infected women who were HPV DNA and HPV seronegative, immune responses to HPV vaccination were generally robust and the vaccine was well tolerated.

References

	Year	Citations
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions New England Journal of Medicine	2007	2K
Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases Suzanne M. Garland, Mauricio Hernández‐Ávila, Cosette M. Wheeler, New England Journal of Medicine	2007	1.9K
Centers for Disease Control and Prevention (CDC) : Advisory Committee on Immunization Practices (ACIP) : Quadrivalent human papillomavirus vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP) Markowitz Le Medical Entomology and Zoology VaccinationImmunization PracticesPreventive MedicineCervical CancerHealth Policy	2007	1.6K
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, The Lancet Oncology VaccinationVaccinologyVaccine DevelopmentCervical CancerHuman Papillomavirus Vaccines	2005	1.6K
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Jorma Paavonen, David Jenkins, F. Xavier Bosch, The Lancet VaccinationVaccine SafetyInterim AnalysisPreventive MedicinePhase Iii Double-blind	2007	1.3K
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta, British Journal of Cancer	2006	804
Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males—Advisory Committee on Immunization Practices (ACIP), 2011 JAMA	2012	577
Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Marguerite Guiguet, François Boué, J. Cadranel, The Lancet Oncology Sexual HealthOncologyHiv Viral LoadTreatment And PreventionAntiviral Therapy	2009	549
Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Infected Women Tedd V. Ellerbrock JAMA	2000	478
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 Luisa L. Villa, Kevin A. Ault, Anna R. Giuliano, Vaccine VaccinationVaccine DevelopmentHuman Papillomavirus VaccinesVaccine TargetImmunology	2006	465

Page 1